Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 2 Interventional

Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence

ClinicalTrials.gov ID: NCT03508648

Public ClinicalTrials.gov record NCT03508648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will enroll only from the first 225 subjects who were randomly assigned to treatment in G201002 (irrespective of the treatment allocation, i.e., GTx-024 or placebo) and who have completed the 12-week treatment period and 16-week durability period to assess the long-term durability of response to GTx-024 on SUI symptoms. The extension study will follow subjects for an additional 20 weeks to help better assess the durability of response in these subjects and will provide additional efficacy and safety data for the subjects. Subjects will not be provided with any study treatments and will be off-drug during this extension study.

Study identification

NCT ID
NCT03508648
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 2
Lead sponsor
GTx
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 27, 2018
Primary completion
Sep 20, 2018
Completion
Sep 20, 2018
Last update posted
Sep 13, 2023

2018

United States locations

U.S. sites
46
U.S. states
25
U.S. cities
46
Facility City State ZIP Site status
Urology Center of Alabama Homewood Alabama 35209
Coastal Clinical Research Inc Mobile Alabama 36608
Alaska Clinical Research Center Anchorage Alaska 99503
Genitourinary Surgical Consultants Denver Colorado 80220
Urology Associates Research Englewood Colorado 80113
Women's Health Specialty Care Farmington Connecticut 06032
Coastal Connecticut Research, LLC New London Connecticut 06320
South Florida Medical Research Aventura Florida 33180
Tampa Bay Medical Research Inc Clearwater Florida 33761
Midland Florida Clinical Research Center LLC DeLand Florida 32720
Medical Research of Florida Miami Florida 33186
Clinical Research Center of Florida Pompano Beach Florida 33060
Mount Vernon Clinical Research LLC Sandy Springs Georgia 30328
Clinical Research Prime Idaho Falls Idaho 83221
Idaho Urologic Institue Meridian Idaho 83642
First Urology PSC Jeffersonville Indiana 47130
Iowa Clinic West Des Moines Iowa 50266
DelRicht Clinical Research, LLC New Orleans Louisiana 70115
Regional Urology Shreveport Louisiana 71106
Chesapeake Urology Associates PA Hanover Maryland 21076
Boston Clinical Trials Boston Massachusetts 02131
Bay State Clinical Trials Watertown Massachusetts 02472
Beyer Research Kalamazoo Michigan 49009
William Beaumont Hospital Urology Research Royal Oak Michigan 48073
Women's Clinic of Lincoln Lincoln Nebraska 68510
Sheldon J Freedman MD Ltd Las Vegas Nevada 89144
Premier Urology Group, LL Edison New Jersey 08837
Lawrence Obs Gyn clinical Research Lawrenceville New Jersey 08648
Delaware Valley Urology Mount Laurel New Jersey 08054
Accumed Research Associates Garden City New York 11530
Manhattan Medical Research Practice PLLC New York New York 10016
Circuit Clinical West Seneca New York 14224
American Health Research Inc Charlotte North Carolina 28207
Eastern Carolina Women's New Bern North Carolina 28562
The Urology Group Cincinnati Ohio 45212
Aventiv Research Columbus Ohio 43213
Institute for Female Pelvic Medicine Allentown Pennsylvania 18103
Urologic Consultants of Southeastern PA LLP Bala-Cynwyd Pennsylvania 19004
University of Pennsylvania Health System Philadelphia Pennsylvania 19104
Coastal Carolina Research Center Mt. Pleasant South Carolina 29464
The Jackson Clinic Jackson Tennessee 38305
Elligo - Austin Area OBGYN Austin Texas 78758
Urology Clinics of North Texas Dallas Texas 75231
Urology San Antonio Research PA San Antonio Texas 78229
Synexus Clinical Research Advantage, Inc. - Wasatch Peak Family Practice Layton Utah 84041
Seattle Womens: Health, Research, Gynocology Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03508648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 13, 2023 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03508648 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →